Evaluation of a PREHABilitation Protocol Using Adapted Physical Activity (APA) for Multiple Myeloma Patients Eligible for Intensive Autologous Stem Cell Transplantation Treatment

NANot yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

February 28, 2028

Study Completion Date

February 28, 2028

Conditions
Multiple Myeloma
Interventions
OTHER

Adapted exercises

"Patients will have 3 sessions a week: 1 strengthening session and 2 endurance sessions.~For each session, patients will choose the exercises to be performed from the exercise booklet or the videos and records their observations in the patient notebook.~Depending on the treatment plan, patients will have alternating supervised (in hospital) and unsupervised (at home) APA sessions, in order to follow the rhythm of their visits to the department.~Each session will last 45 minutes with a medium intensity according to the Borg scale."

OTHER

No intervention

Patients will not be practising adapted exercises as part of the study. They will be treated with chemotherapy according to standard practice.

BEHAVIORAL

Quality of Life questionnaire

QoL questionnaire (EORTC QLQ-C30) at baseline, mid-term (after 2 cycles of chemotherapy), before transplantation, and after transplantation

BEHAVIORAL

Questionnaire of Fatigue

Questionnaire (EORTC QLQ-FA12) at baseline, mid-term (after 2 cycles of chemotherapy), before transplantation, and after transplantation

BEHAVIORAL

Physical activity questionnaire

Questionnaire (IPAQ) at baseline and after transplantation

BEHAVIORAL

Physical condition

Evaluation of physical condition at baseline, mid term (after 2 cycles of chemotherapy), before transplantation and after transplantation

Trial Locations (1)

Unknown

Centre Hospitalier d'Avignon, Hôpital Henri Duffaut, Avignon

All Listed Sponsors
lead

Centre Hospitalier Henri Duffaut - Avignon

OTHER

NCT06789003 - Evaluation of a PREHABilitation Protocol Using Adapted Physical Activity (APA) for Multiple Myeloma Patients Eligible for Intensive Autologous Stem Cell Transplantation Treatment | Biotech Hunter | Biotech Hunter